Development of dds using hollow bio-nanoparticles and their commercialization

Akihiko Kondo, Shun ichi Kuroda, Katsuyuki Tanizawa, Masaharu Seno, Masakazu Ueda

Research output: Contribution to journalArticle

Abstract

We succeeded overproduction of the HBV envelope L particles with an approximate average particle size of 80 nm in yeast cells. Because the L particle is an empty bionanoparticles containing no viral DNA, it can be used as a safe and efficient carrier for human liver-specific delivery (pinpoint delivery) of drug and gene. In addition, genetically engineered L particles that are able to target to various organs were constructed by deleting the hepatocyte binding domain of L protein (pre-S region) and displaying targeting peptide or protein ligands. Therefore, bionanoparticles are a novel nano-carrier applicable to the broad range of pinpoint DDS.

Original languageEnglish
Pages (from-to)435-443
Number of pages9
JournalDrug Delivery System
Volume21
Issue number4
DOIs
Publication statusPublished - 2006

Keywords

  • gene therapy
  • hepatitis B virus
  • nanoparticle
  • pinpoint drug delivery
  • targeting

ASJC Scopus subject areas

  • Pharmaceutical Science

Fingerprint Dive into the research topics of 'Development of dds using hollow bio-nanoparticles and their commercialization'. Together they form a unique fingerprint.

Cite this